Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 21;3(1):34.
doi: 10.1186/s42466-021-00135-y.

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Max Borsche  1   2 , Dirk Reichel  3 , Anja Fellbrich  2 , Anne S Lixenfeld  4 , Johann Rahmöller  4   5 , Eva-Juliane Vollstedt  1 , Bandik Föh  4   6 , Alexander Balck  1   2 , Christine Klein  1 , Marc Ehlers  4 , Andreas Moser  7   8
Affiliations

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Max Borsche et al. Neurol Res Pract. .

Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

Keywords: COVID-19; CSF antibodies; Cognitive impairment; Neurologic sequelae; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, Kotanidou A, Dalakas MC. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurology – Neuroimmunology & Neuroinflammation. 2020;7(6):e893. doi: 10.1212/NXI.0000000000000893. - DOI - PMC - PubMed
    1. Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. Journal of Virology. 2011;85(23):12464–12473. doi: 10.1128/JVI.05576-11. - DOI - PMC - PubMed
    1. Förster, M., Weyers, V., Küry, P., Barnett, M., Hartung, H.-P., & Kremer, D. (2020). Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy ‘gone viral’. Brain Communications, 2(2), fcaa149. 10.1093/braincomms/fcaa149 - PMC - PubMed
    1. Josephson SA, Kamel H. Neurology and COVID-19. JAMA. 2020;324(12):1139–1140. doi: 10.1001/jama.2020.14254. - DOI - PubMed
    1. Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püschel K, Krasemann S, Aepfelbacher M, Glatzel M. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurology. 2020;19(11):919–929. doi: 10.1016/S1474-4422(20)30308-2. - DOI - PMC - PubMed